In conclusion, the novel miR-34a-guided, tRNAiMet-derived fragment tRiMetF31, which was downregulated in cancer cell lines, suppresses migration and angiogenesis of breast cancer cells via targeting PFKFB3 (Fig. 7F), and that can be reversed by tRiMetF31 knockdown, highlighting a crucial anti-angiogenic role of miR-34a/tRiMetF31/PFKFB3 axis in breast cancer progression. Here, PFKFB3 is linked to breast carcinoma.